SSY Group’s Dialysis Solution Gains Regulatory Approval

SSY Group ( (HK:2005) ) has provided an update.

SSY Group Limited has announced that its Low Calcium Peritoneal Dialysis Solution has passed the Consistency Evaluation of the Quality and Efficacy of Generic Drugs by the National Medical Products Administration of China. This development marks a significant advancement for the company, enhancing its product offerings in the treatment of renal failure and potentially strengthening its position in the pharmaceutical market.

The most recent analyst rating on (HK:2005) stock is a Buy with a HK$7.00 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.

More about SSY Group

SSY Group Limited operates in the healthcare industry, focusing on the development and production of pharmaceutical products. The company specializes in generic drugs, with a market focus on providing medical solutions for patients with renal failure.

Average Trading Volume: 7,548,251

Technical Sentiment Signal: Sell

Current Market Cap: HK$8.88B

For detailed information about 2005 stock, go to TipRanks’ Stock Analysis page.